Comparative Pharmacology
Head-to-head clinical analysis: NELARABINE versus TIBSOVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NELARABINE versus TIBSOVO.
NELARABINE vs TIBSOVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
Isocitrate dehydrogenase-2 (IDH2) inhibitor; targets mutant IDH2 isoforms to reduce 2-hydroxyglutarate (2-HG) levels, promoting myeloid differentiation.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
500 mg orally once daily taken with or without food.
None Documented
None Documented
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Clinical Note
moderateNelarabine + Digoxin
"Nelarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNelarabine + Digitoxin
"Nelarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNelarabine + Deslanoside
"Nelarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNelarabine + Acetyldigitoxin
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 50-60 hours, supporting once-daily dosing with steady-state reached in approximately 2 weeks.
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Primarily hepatic metabolism (CYP3A4) and fecal excretion (77% unchanged and metabolites); renal elimination accounts for <1% of absorbed dose.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent